Comparative Pharmacology
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus BANTHINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANISOTROPINE METHYLBROMIDE versus BANTHINE.
ANISOTROPINE METHYLBROMIDE vs BANTHINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anisotropine methylbromide is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors (M1, M2, M3), thereby inhibiting parasympathetic nerve impulses. This leads to relaxation of smooth muscle in the gastrointestinal tract, decreased gastric acid secretion, and reduced motility.
Anticholinergic; competitively blocks muscarinic acetylcholine receptors, inhibiting parasympathetic impulses.
Adult: 1-2 mg intramuscularly or subcutaneously every 4-6 hours as needed. Maximum: 8 mg/day.
Adults: 50 mg orally four times daily, before meals and at bedtime.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours).
Clinical Note
moderateAnisotropine methylbromide + Fesoterodine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Fesoterodine."
Clinical Note
moderateAnisotropine methylbromide + Quinidine
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Quinidine."
Clinical Note
moderateAnisotropine methylbromide + Topiramate
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Topiramate."
Clinical Note
moderateTerminal elimination half-life is approximately 2.5–3 hours in adults with normal renal function. In elderly or those with renal impairment, half-life may be prolonged to 6–8 hours, requiring dose adjustment.
Primarily renal (approx. 70-80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 20-30%, mainly as metabolites.
BANTHINE (methantheline) is primarily eliminated via renal excretion (approximately 70% unchanged) with the remainder as metabolites. Biliary/fecal elimination accounts for less than 15%. Total recovery in urine and feces is nearly complete.
Category C
Category C
Anticholinergic
Anticholinergic
Anisotropine methylbromide + Methadone
"The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Methadone."